321 related articles for article (PubMed ID: 26638884)
1. Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies.
Salarinia R; Sahebkar A; Peyvandi M; Mirzaei HR; Jaafari MR; Riahi MM; Ebrahimnejad H; Nahand JS; Hadjati J; Asrami MO; Fadaei S; Salehi R; Mirzaei H
Curr Cancer Drug Targets; 2016; 16(9):773-788. PubMed ID: 26638884
[TBL] [Abstract][Full Text] [Related]
2. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
[TBL] [Abstract][Full Text] [Related]
3. Dual targeting of epigenetic therapy in cancer.
Hellebrekers DM; Griffioen AW; van Engeland M
Biochim Biophys Acta; 2007 Jan; 1775(1):76-91. PubMed ID: 16930846
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic therapy for solid tumors: from bench science to clinical trials.
Juo YY; Gong XJ; Mishra A; Cui X; Baylin SB; Azad NS; Ahuja N
Epigenomics; 2015; 7(2):215-35. PubMed ID: 25942532
[TBL] [Abstract][Full Text] [Related]
5. DNA demethylating agents and epigenetic therapy of cancer.
Mani S; Herceg Z
Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
[TBL] [Abstract][Full Text] [Related]
6. Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
Teixeira SR; Abreu CM; Parkes L; Davies J; Yao S; Sawhney MA; Margarit L; Gonzalez D; Pinto IM; Francis LW; Conlan RS
Biosens Bioelectron; 2019 Sep; 141():111386. PubMed ID: 31220725
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic drugs take on cancer.
Kaiser J
Science; 2010 Oct; 330(6004):576-8. PubMed ID: 21030620
[No Abstract] [Full Text] [Related]
9. Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer.
Raynal NJ; Lee JT; Wang Y; Beaudry A; Madireddi P; Garriga J; Malouf GG; Dumont S; Dettman EJ; Gharibyan V; Ahmed S; Chung W; Childers WE; Abou-Gharbia M; Henry RA; Andrews AJ; Jelinek J; Cui Y; Baylin SB; Gill DL; Issa JP
Cancer Res; 2016 Mar; 76(6):1494-505. PubMed ID: 26719529
[TBL] [Abstract][Full Text] [Related]
10. Manipulating the epigenome for the treatment of urological malignancies.
O'Rourke CJ; Knabben V; Bolton E; Moran D; Lynch T; Hollywood D; Perry AS
Pharmacol Ther; 2013 May; 138(2):185-96. PubMed ID: 23353098
[TBL] [Abstract][Full Text] [Related]
11. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
Shin H; Kim JH; Lee YS; Lee YC
Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
Teodoridis JM; Strathdee G; Brown R
Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
[TBL] [Abstract][Full Text] [Related]
13. Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract.
Wang Z; Yue Y; Han P; Sa R; Ren X; Wang J; Bai H; Yu H
Cytotherapy; 2013 Sep; 15(9):1164-73. PubMed ID: 23800731
[TBL] [Abstract][Full Text] [Related]
14. Trials with 'epigenetic' drugs: an update.
Nebbioso A; Carafa V; Benedetti R; Altucci L
Mol Oncol; 2012 Dec; 6(6):657-82. PubMed ID: 23103179
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional Selectivity of Epigenetic Therapy in Cancer.
Sato T; Cesaroni M; Chung W; Panjarian S; Tran A; Madzo J; Okamoto Y; Zhang H; Chen X; Jelinek J; Issa JJ
Cancer Res; 2017 Jan; 77(2):470-481. PubMed ID: 27879268
[TBL] [Abstract][Full Text] [Related]
16. Epi-drugs as triple-negative breast cancer treatment.
Idrissou M; Sanchez A; Penault-Llorca F; Bignon YJ; Bernard-Gallon D
Epigenomics; 2020 Apr; 12(8):725-742. PubMed ID: 32396394
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic cancer therapies: DNA methyltransferase inhibitors.
Strathdee G; Brown R
Expert Opin Investig Drugs; 2002 Jun; 11(6):747-54. PubMed ID: 12036419
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic drug discovery: targeting DNA methyltransferases.
Foulks JM; Parnell KM; Nix RN; Chau S; Swierczek K; Saunders M; Wright K; Hendrickson TF; Ho KK; McCullar MV; Kanner SB
J Biomol Screen; 2012 Jan; 17(1):2-17. PubMed ID: 21965114
[TBL] [Abstract][Full Text] [Related]
19. Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications.
Mund C; Brueckner B; Lyko F
Epigenetics; 2006; 1(1):7-13. PubMed ID: 17998812
[TBL] [Abstract][Full Text] [Related]
20. DNA hypermethylation as a chemotherapy target.
Ren J; Singh BN; Huang Q; Li Z; Gao Y; Mishra P; Hwa YL; Li J; Dowdy SC; Jiang SW
Cell Signal; 2011 Jul; 23(7):1082-93. PubMed ID: 21345368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
